Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803.
Yosuke Kawashima(Sendai Kousei Hospital), Toshihiro Nukiwa(Tohoku University), Akira Inoue(Tohoku University Hospital), Tomohiro Sakakibara(Tohoku University Hospital), Hajime Asahina(Hokkaido University), Akiko Hisamoto(Okayama University), Shoichi Kuyama(Iwakuni Medical Center), Toshiyuki Kozuki(Shikoku Cancer Center), Shunichi Sugawara(Sendai Kousei Hospital), Kunihiko Kobayashi(Saitama Medical University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Masao Harada(Shikoku Cancer Center), Taku Nakagawa(Saint John's Health Center)
Cited by 6
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953